Key Highlights
- On July 22, 2026, Lakewood-Amedex Biotherapeutics (LABT) published resistance study results for Nu-3, its Phase 2-ready antimicrobial asset.
- Serial passage experiments demonstrated Nu-3 did not trigger resistance development in bacterial strains.
- Nu-3 employs a physical membrane-disrupting approach to combat infected diabetic foot ulcers.
- Laboratory studies confirmed effectiveness against diverse resistant bacterial strains, including MRSA and VRE.
- Trading at approximately $1.86—near its 52-week low—LABT maintains a market capitalization of around $3.26 million.
On July 22, 2026, Lakewood-Amedex Biotherapeutics (LABT) unveiled resistance study findings for Nu-3, its primary antimicrobial development candidate. Following the announcement, shares experienced a dramatic spike, climbing more than 141% during the trading session.
Lakewood-Amedex Biotherapeutics Inc. Common Stock, LABT
LABT operates as a clinical-stage biotechnology company with a modest market capitalization of $3.26 million. Prior to today’s surge, shares were changing hands at $1.86, hovering near the 52-week low point of $1.66.
Nu-3 belongs to the company’s proprietary Bisphosphocin antimicrobial platform. The therapeutic candidate targets treatment of mildly infected diabetic foot ulcers.
The critical discovery: serial passage testing revealed Nu-3 failed to trigger resistance development. This represents a significant outcome for a therapeutic addressing antibiotic-resistant bacterial infections.
In contrast to conventional antibiotics, Nu-3 operates through physical disruption of bacterial cell membranes. This operational mechanism creates substantial barriers for bacteria attempting to develop resistance through typical evolutionary pathways.
Laboratory evaluations demonstrated Nu-3 maintained effectiveness against bacterial strains possessing diverse resistance characteristics. These encompassed modified antibiotic binding sites, direct antibiotic degradation enzymes, and active efflux transport systems.
Bacterial Strains Evaluated
The study encompassed 14 distinct bacterial species. Among these were E. coli, S. aureus, P. aeruginosa, K. pneumoniae, and A. baumannii — representing some of the most challenging drug-resistant pathogens encountered in healthcare environments.
Particular resistance phenotypes examined included vanA and vanB genes, mecA expression, rpoB mutations, NDM carbapenemase, ESBL production, AmpC expression, CRE mechanisms, sul2 resistance, and benzalkonium chloride efflux systems. This constitutes comprehensive coverage of resistance pathways.
Testing parameters also incorporated PBP2x genetic variants and metal-tetracycline/H+ antiporter-mediated resistance. In vitro results showed Nu-3 retained activity against each mechanism.
Policy Environment Context
This data release comes after the 27th Public Meeting of the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB), convened on June 16, 2026. The meeting centered on developing the upcoming five-year National Action Plan on Combating Antibiotic-Resistant Bacteria.
The Nu-3 findings correspond with objectives established during that session, which established priorities for federal antimicrobial resistance initiatives.
Company insiders hold 69.22% of outstanding shares, suggesting substantial confidence from management and early stakeholders.
Records indicate no insider transactions—either purchases or sales—during the preceding three-month period.
LABT currently produces no revenue and continues to report operating losses. The company’s GF Score registers at 8 out of 100, with profitability metrics at 1/10 and financial strength assessed at 4/10.
Nu-3 has achieved Phase 2-ready status for addressing mildly infected diabetic foot ulcers. The company has not disclosed a timeline for initiating Phase 2 clinical trials.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
